Golimumab (Simponi) for the indications 'Moderate to Severe Rheumatoid Arthritis (RA)', 'Active Psoriatic Arthritis (PsA)', and 'Active Ankylosing Spondylitis (AS)'
This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.
